S6 Ep42: Jabbour Highlights New Data With Asciminib and Ponatinib in CML
OncLive® On Air
00:00
OPTIC Post-hoc: Mutation-Specific Ponatinib Dosing
Elias Jabbour explains an OPTIC post-hoc analysis showing T315I benefits from 45 mg, while lower doses may suffice without mutations.
Play episode from 08:41
Transcript
